A5058242506- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Cancer Genomics and Diagnostics
- Acute Lymphoblastic Leukemia research
- Statistical Methods in Clinical Trials
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Global Health Care Issues
- Health and Medical Studies
- Scientific Computing and Data Management
- Renal and related cancers
- Healthcare Policy and Management
- Renal cell carcinoma treatment
- Machine Learning in Healthcare
- Renal Diseases and Glomerulopathies
- Gene Regulatory Network Analysis
- T-cell and B-cell Immunology
- Cancer Treatment and Pharmacology
- Economic and Financial Impacts of Cancer
- Cervical Cancer and HPV Research
- Platelet Disorders and Treatments
- Colorectal Cancer Screening and Detection
- Gene expression and cancer classification
- Evolution and Genetic Dynamics
Zimmer Biomet (Germany)
2017-2023
TU Dresden
2016-2023
University Hospital Carl Gustav Carus
2017-2023
Carl Gustav Carus-Institut
2023
Alliance for Clinical Trials in Oncology
2016
Western Michigan University
2005
The effect of different invitation models on participation in cervical cancer screening (CCS) was investigated a randomized population‐based cohort study Germany. Participants were randomly selected via population registries and into intervention Arm A (invitation letter) B letter information brochure) or control C (no invitation). arms compared with regard to 3‐year the two between arms. Of 7,758 eligible women aged 30–65 years, living city Mainz rural region Mainz‐Bingen, 5,265 included...
Abstract Several studies have reported that chronic myeloid leukaemia (CML) patients expressing e14a2 BCR::ABL1 a faster molecular response to therapy compared e13a2. To explore the reason for this difference we undertook detailed technical comparison of commonly used Europe Against Cancer (EAC) reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) assay in European Treatment and Outcome Study (EUTOS) reference laboratories ( n = 10). We found amplification ratio e13a2...
The transfer of new insights from basic or clinical research into routine is usually a lengthy and time-consuming process. Conversely, there are still many barriers to directly provide use data in the context research. In particular, no coherent software solution available that allows convenient immediate bidirectional between concrete treatment contexts settings. Here, we present generic framework integrates health (e.g., clinical, molecular) computational analytics model predictions,...
Abstract Background Effects of demographic change, such as declining birth rates and increasing individual life expectancy, require health system adjustments offering age- needs-based care. In addition, healthcare factors can also influence services demand. Methods The official German hospital statistics database with odd-numbered years between 1995 2011 was analysed. This is a national comprehensive all general inpatient delivered. Official data from were linked at the district level...
Abstract Response to tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML) is monitored by quantification of BCR::ABL1 transcript levels. Milestones for assessing optimal treatment response have been defined adult CML and are applied children adolescents although it questionable whether transferability pediatric appropriate regarding genetic clinical differences. Therefore, we analyzed the molecular kinetics TKI 129 investigated assessment based on...
Risk stratification and treatment decisions for leukemia patients are regularly based on clinical markers determined at diagnosis, while measurements system dynamics often neglected. However, there is increasing evidence that linking quantitative time-course information to disease outcomes can improve the predictions patient-specific responses. We designed a synthetic experiment simulating response kinetics of 5,000 compare different computational methods with respect their ability...
You have accessJournal of UrologyKidney Cancer: Advanced I1 Apr 2015PD35-08 POLYMORPHISMS IN VEGFA, VEGFR1, -2 AND -3 ARE ASSOCIATED WITH RESPONSE OUTCOME OF SUNITINIB-TREATED METASTATIC RENAL CELL CARCINOMA PATIENTS Juana Dornbusch, Martina Walter, Andrea Gottschalk, Alice Obaje, Kerstin Junker, Carsten-Henning Ohlmann, Matthias Meinhardt, Aristeidis Zacharis, Stefan Zastrow, Marc-Oliver Grimm, Stefanie J. Klug, Susanne Fuessel, and Manfred P. Wirth DornbuschJuana Dornbusch More articles by...
Topic: 8. Chronic myeloid leukemia - Clinical Background: The transfer of new insights from basic or clinical research into routine is usually a lengthy and time-consuming process. Conversely, there are still many barriers to directly provide use data in the context research. In particular, no coherent software solution available that allows for convenient immediate bidirectional between treatment situations settings. Aims: We aim develop generic concept context-depending data-sharing...
ABSTRACT Thrombopoietin (TPO) is the ligand of Mpl receptor and key regulator megakaryopoiesis platelet production. A loss or gain TPO-receptor function affects haematopoiesis results in severe diseases humans. Appropriate mouse strains are available to mimic both myeloproliferative neoplasm (MPN) congenital amegakaryocytic thrombocytopenia (CAMT) resulting from TPO overexpression knockout on megakaryocytes platelets, respectively. However, at a quantitative level it not understood, how...
Background Optimal treatment of pediatric CML requires a patient specific risk stratification and the comparability individual therapy responses. A deeper understanding cells eradication dynamic is needed to make earlier decisions. Methods: Besides transcript-based monitoring, DNA-based quantification was performed using droplet digital PCR (ddPCR). total 1348 specimens from 65 patients were included. Therapy response models designed separately for RNA-/DNA-monitoring. Data evaluated moving...
Abstract Risk stratification and treatment decisions for leukemia patients are regularly based on clinical markers determined at diagnosis, while measurements system dynamics often neglected. However, there is increasing evidence that linking quantitative time-course information to disease outcomes can improve the predictions patient-specific responses. We designed a synthetic experiment compare different computational methods with respect their ability accurately predict relapse chronic...
Risk stratification and treatment decisions for leukaemia patients are regularly based on clinical markers determined at diagnosis, while measurements system dynamics often neglected. However, there is increasing evidence that linking quantitative time-course information to disease outcomes can improving the predictions patient-specific response.We analyzed potential of different computational methods accurately predict relapse chronic acute myeloid leukaemia, particularly focusing influence...
Abstract Usually, it takes quite some time until new insights from basic or clinical research are ultimately transferred into routine. On the other hand, there still many hurdles to directly provide and use routine data in context of research. Specifically, no coherent software solution is available that allows a convenient immediate bidirectional transfer between concrete treatment contexts settings. Here, we present generic framework integrates health (e.g., clinical, molecular)...